# GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab

> **NCT06338553** · EARLY_PHASE1 · RECRUITING · sponsor: **Vanderbilt University Medical Center** · enrollment: 24 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** Semaglutide (Rybelsus®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06338553
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06338553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06338553, "GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06338553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*